Agenda
The following agenda is for the 2026 Quarterly Meetings event.
Wednesday, July 15th, 2026
| Time | Event/Topic |
|---|---|
| 5:15 PM | Dinner selections taken |
| 5:30 PM - 6:15 PM | Product Theater Hosted by Incyte Monjuvi + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination for 2L+ Follicular Lymphoma Patients |
| 6:15 PM - 6:45 PM | Reception/Dinner |
| 6:45 PM - 8:45 PM | Case Presentations/Discussion will focus on Lymphoma Justin Kline, MD Director, Lymphoma Program U Chicago Medicine |